Join us at 14:00 Central European Time (13:00 London) on Weds 25th May 2022, for a discussion with Roberto Pistolesi, FICPI Secretary General, and CEO and Partner of Dragotti & Associati in Italy

Roberto PistolesiRoberto will discuss:

  • Why is golf the number 1 sport for patents?
  • When did inventors (or alleged inventors) start filing golf-related patent applications?
  • What did they cover and what do they cover now?
  • Who are the bigger filers?
  • What happened to NIKE’s patent portfolio?
  • Are golf-related patents frequently litigated?


Roberto Pistolesi has extensive experience both in prosecution and opposition procedures before the EPO, where he has been involved in more than 50 cases before the Opposition Divisions or the Boards of Appeal. He also has a wide expertise in multi-national patent litigations, having been involved in several litigations both in Italy and abroad (mainly USA, UK, Germany and France). In particular, he has been involved in patent litigations concerning the following active principles: alendronic acid, atorvastatin, cefaclor, citalopram, docetaxel, enoxaparin,esomeprazole, phosphatidylserine, gabapentin, irbesartan + HCT, latanoprost, olanzapine, omega-3, omeprazole, montelukast, quetiapine, ramipril, repaglinide, rupatadine, salmeterol + fluticasone, and terbinafine. He frequently advises clients on patent strategies and provides infringement and validity opinions.

Roberto has been a technical expert of the Court of Milan since 2002 and of the Court of Venice since 2015, where he assists Judges in patent infringement and/or validity cases.

He was also adjunct Professor at the “Universita’ degli Studi” of Milan from 2011 to 2015, where he taught chemical patent practice to the students of Chemical Science, Industrial Chemistry and Biotechnology.

He has been the Secretary General of FICPI since April 2015. He was the chairman of FICPI’s study and work commission dealing with inventions in the pharma and biotech area from April 2012 to April 2015.

He frequently lectures on intellectual property both in Italy and abroad.
He has published several articles on “Il Sole-24 Ore”, “Pharmachem” and “Il Diritto Industriale”; he is co-author of the Italian and European sections of “Biotechnology and Pharmaceutical Patents – Law and Practice”, Wolters Kluwer, 2008 and 2009 editions.

This session is the last in our current webinar and podcast series "FICPI Focus 45".


CPD/CLE certificates are available for this event.

FICPI's webinar host:

Louis-Pierre Gravelle -- Partner at Bereskin & Parr in Canada and Vice President of FICPI's Professional Excellence Committee

Louis-Pierre Gravelle of Bereskin & Parr specialises in the drafting and prosecution of patent applications and providing patentability, validity, infringement and right to manufacture opinions in the fields of electricity, telecommunications, mechanical and information technology. He is a registered patent agent in Canada and in the United States (1998).

Louis-Pierre is involved in due diligence matters and managing patent portfolios. He is also involved in strategic counselling for start-ups, small, medium and large-sized businesses.

A member of the Intellectual Property Institute of Canada (IPIC) and the Canadian Bar Association (CBA), Louis-Pierre was called to the Québec Bar in 1995. He is also a member of the Ordre des ingénieurs du Québec (OIQ). Louis-Pierre Gravelle is past-chair of the Intellectual Property Section of the Canadian Bar Association (CBA) and past co-president of the Joint Liaison Committee – Patents between the Patent office and IPIC. He is a Councillor for FICPI Canada.

He is listed in the IAM Patents 1000, and has been since 2012. Louis-Pierre is often called upon to speak on a variety of IP-related topics, at local and international conferences and events.


Previous Post
Help for Ukraine